Laser Interstitial Thermal Therapy in Grade 2/3 Mutant Gliomas: A Preliminary Report and Literature Review.

Laser interstitial thermal therapy (LITT) has become an increasingly utilized alternative to surgical resection for the treatment of glioma in patients. However, treatment outcomes in isocitrate dehydrogenase 1 and 2 () mutant glioma, specifically, have not been reported. The objective of this study was to characterize a single institution's cohort of mutant grade 2/3 glioma patients treated with LITT. We collected data on patient presentation, radiographic features, tumor molecular profile, complications, and outcomes. We calculated progression-free survival (PFS) and tested factors for significant association with longer PFS. Overall, 22.7% of our cohort experienced progression at a median follow up of 1.8 years. The three- and five-year estimates of PFS were 72.5% and 54.4%, respectively. This is the first study to characterize outcomes in patients with mutant glioma after LITT. Our results suggest that LITT is an effective treatment option for mutant glioma.